EUVIMEDEUVIMED entdecken
Crossref

Respiratory and Bulbar Support in Spinal Muscular Atrophy Type I Treated with Nusinersen

Guillaume Gauvreau, Tarannum Behlim, Pamela Ng, Victoria Hodgkinson iD, Kathryn Selby, Jean K Mah iD, Hanna Kolski iD, Maria Castro-Codesal, Megan Crone, Edward Leung, Kristina Joyal, Craig Campbell und 7 weitere

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · 2026

DOI: 10.1017/cjn.2025.74 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2026. Verfasst von Guillaume Gauvreau und 18 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, McGill University, Montreal, QC, Canada. Hauptthemen laut MEDLINE: Spinal Muscular Atrophies of Childhood, Oligonucleotides, Respiration, Artificial. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The aim of this study is to assess the evolution of respiratory and feeding support in children with spinal muscular atrophy (SMA) type 1 after 24 months of nusinersen treatment.

Methods

Data on SMA type 1 children treated with nusinersen between 2017 and 2023 from the Canadian Neuromuscular Disease Registry were extracted. The cohort was divided into two groups based on age at treatment initiation: ≤2 years and >2 years. The primary outcome was the (i) time to death or needing full-time (≥16 hours/day) ventilation and (ii) time to needing feeding tube support. The secondary outcomes were differences in respiratory and feeding support requirements between the two groups at 24-month follow-up.

Results

Thirty-two children were included, and the median age (range) for treatment initiation was 3.2 months (0.8– 13.1) in children who initiated treatment at ≤2 years and 51.2 (28.7–183.8) in those who initiated at >2 years of age. The median age of death or full-time ventilation was 8.6 months (6–22.4) and 10.5 months (4–24) for the two groups, respectively. The median age for initiation of feeding support was 5.1 (1.7–26.4) and 14.5 months (3.9–130.6), respectively. At 24 months ( n = 23), there were no significant differences between the need for respiratory or feeding tube support between the two treatment groups.

Conclusion

Most children with SMA type 1 treated with nusinersen across Canada have continued need for respiratory and feeding support over time when initiated after symptom onset.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spinal Muscular Atrophies of ChildhoodOligonucleotidesRespiration, ArtificialHumansFemaleMaleInfantChild, PreschoolChildTreatment OutcomeCohort StudiesCanadaFollow-Up StudiesRegistries

Stichwörter der Autor:innen

clinical epidemiologyneurology – pediatricneuromuscular disordersneuromuscular – pediatricspinal muscular atrophy

Substanzen

nusinersenOligonucleotides

Autor:innen und Institutionen

  • Faculty of Medicine, McGill University, Montreal, QC, Canada.
  • Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Center, Montreal, QC, Canada.
  • Department of Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
  • Division of Neurology, Department of Pediatrics, BC Children's Hospital, University of British Columbia Vancouver, Vancouver, Canada.
  • Department of Pediatrics, University of Calgary, Calgary, Canada.
  • Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.

ORCID-Profile: Victoria Hodgkinson, Jean K Mah, Hanna Kolski, Hugh McMillan, Maryam Oskoui

Zitieren

APA

Gauvreau, G., Behlim, T., Ng, P., Hodgkinson, V., Selby, K., Mah, J. K., Kolski, H., Castro-Codesal, M., Crone, M., Leung, E., Joyal, K., Campbell, C., McAdam, L., Gonorazky, H., McMillan, H., McCormick, A., O'Connell, C., Taillon, M., & Oskoui, M. (2026). Respiratory and Bulbar Support in Spinal Muscular Atrophy Type I Treated with Nusinersen. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. https://doi.org/10.1017/cjn.2025.74

Vancouver

Gauvreau G, Behlim T, Ng P, Hodgkinson V, Selby K, Mah JK, et al. Respiratory and Bulbar Support in Spinal Muscular Atrophy Type I Treated with Nusinersen. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 2026. doi:10.1017/cjn.2025.74

BibTeX
@article{Gauvreau2026,
  author = {Gauvreau, Guillaume and Behlim, Tarannum and Ng, Pamela and Hodgkinson, Victoria and Selby, Kathryn and Mah, Jean K and Kolski, Hanna and Castro-Codesal, Maria and Crone, Megan and Leung, Edward and Joyal, Kristina and Campbell, Craig and McAdam, Laura and Gonorazky, Hernan and McMillan, Hugh and McCormick, Anna and O'Connell, Colleen and Taillon, Monique and Oskoui, Maryam},
  title = {Respiratory and Bulbar Support in Spinal Muscular Atrophy Type I Treated with Nusinersen},
  journal = {Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques},
  year = {2026},
  doi = {10.1017/cjn.2025.74}
}
Kostenlos starten →